Business Wire

New Digital Trust Research Reveals Gaps, Benefits and Key Takeaways for Future Digital Transformation

15.9.2022 15:00:00 EEST | Business Wire | Press release

Share

As enterprises worldwide race toward digital transformation, the State of Digital Trust 2022 survey report from ISACA shows significant gaps between what enterprises are doing now and what they should do to establish leadership and earn customer trust in the future digital ecosystem.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220915005265/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

ISACA surveyed more than 2,700 professionals worldwide who hold assurance, governance, risk, security or privacy roles to learn how enterprises are approaching digital trust. See key findings in this infographic, and access five takeaways on how to advance digital trust in the free survey report at www.isaca.org/state-of-digital-trust. (Photo: ISACA)

The report features insights from 2,755 international business and information technology professionals. ISACA defines digital trust as the confidence in the integrity of relationships, interactions and transactions among providers and consumers within an associated digital ecosystem.

While 98 percent of respondents say that digital trust is important, only 12 percent of their organizations have a dedicated staff role for digital trust.

Looking ahead, 82 percent say digital trust will be even more important in five years, yet only 29 percent offer staff digital trust training.

“Digital trust is the bedrock of business relationships, and is critical for strategic digital transformation,” said David Samuelson, chief executive officer, ISACA. “Innovation, market leadership and financial performance rely heavily on trust that must be earned every day.”

Organizations with low digital trust experience reputation decline (62 percent), more privacy breaches (60 percent), more cybersecurity incidents (59 percent), lost customers (56 percent), less reliable data for decisions (53 percent), negative revenue impact (43 percent) and slower innovation (36 percent).

Obstacles

The most significant obstacles to digital trust are lack of skills and training (53 percent), lack of alignment with enterprise goals (44 percent), lack of leadership buy-in (42 percent), lack of budget (41 percent) and lack of technological resources (40 percent).

“Digital trust is a currency that must be backed by a robust validation process,” said Matt Chiodi, chief trust officer, Cerby, and a member of ISACA’s Digital Trust Council. “Trust must be earned, which means that in everything an organization does, the end goal must be answering the question, ‘What can we do today to better earn the trust of our customers?’ Those organizations that continually ask this question and make executing on the answers a priority will win in the future – win in market share, profitability and engagement with employees and customers.”

Benefits

Key benefits of having high levels of digital trust include:

  • Positive reputation (66 percent)
  • Fewer privacy breaches (58 percent)
  • Fewer cybersecurity incidents (57 percent)
  • Stronger customer loyalty (55 percent)
  • Faster innovation (44 percent)
  • Higher revenue (25 percent)

Growth opportunities

Respondents said the top three components of digital trust are security, data integrity and privacy, but only half agree there is sufficient collaboration among professionals in these and other digital trust fields.

Eighty-two percent say digital trust will be much more important in their organization and 28 percent say their organization will likely have a senior staff role dedicated to digital trust in five years.

Visit www.isaca.org/digital-trust or www.isaca.org/state-of-digital-trust for the State of Digital Trust report and resources.

Access a member-only sneak peek webinar about the new Digital Trust Ecosystem Framework at 12 pm ET on 22 September 2022.

About ISACA

ISACA® (www.isaca.org) is a global community advancing individuals and organizations in their pursuit of digital trust. For more than 50 years, ISACA has equipped individuals and enterprises with the knowledge, credentials, education, training and community to progress their careers, transform their organizations, and build a more trusted and ethical digital world. ISACA has more than 165,000 members in 188 countries, including 225 chapters worldwide. Through its foundation One In Tech, ISACA supports IT education and career pathways for underresourced and underrepresented populations.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Emily Van Camp, +1.847.385.7217, communications@isaca.org
Kristen Kessinger, +1.847.660.5512, kkessinger@isaca.org

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release

IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye